Moderna and Merck's Personalized mRNA Melanoma Vaccine Clears Phase 3, Hits Main Goal

SentiSense · Published · Updated

Moderna and Merck announced that their personalized mRNA vaccine for melanoma met its primary endpoint in a large Phase 3 trial, marking a breakthroug...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis